Aryana Sepassi

Dr. Aryana Sepassi


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in The Oncologist
Verified
Journal Article
Open access
PDF file
ASAryana Sepassi
Aryana Sepassi
MLMeng Li
Meng Li
JZJason A. Zell
Jason A. Zell
ACAlexandre Chan
Alexandre Chan
ISIla M Saunders
Ila M Saunders
DMDana B Mukamel
Dana B Mukamel
Background: Rural residents have a higher prevalence of colorectal cancer (CRC) mortality compared to urban individuals. Policies have been aimed at improving access to CRC screening to reduce these outcomes. However, little attention has been paid to other determinants of CRC-related outcomes, such as stage at diagnosis, treatment, or survivorship care. The main objective of this analysis was to evaluate literature describing differences in CRC screening, stage at diagnosis, treatment, and survivorship care between rural and urban individuals. Materials and Methods: We conducted a systematic review of electronic databases using a combination of MeSH and free-text search terms related to CRC screening, stage at diagnosis, treatment, survivorship care, and rurality. We identified 921 studies, of which 39 were included. We assessed methodological quality using the ROBINS-E tool and summarized findings descriptively. A meta-analysis was performed of studies evaluating CRC screening using a random-effects model. Results: Seventeen studies reported disparities between urban and rural populations in CRC screening, 12 on treatment disparities, and 8 on staging disparities. We found that rural individuals were significantly less likely to report any type of screening at any time period (pooled odds ratio = 0.81, 95% CI, 0.76-0.86). Results were inconclusive for disparities in staging at diagnosis and treatment. One study reported a lower likelihood of use of CRC survivorship care for rural individuals compared to urban individuals. Conclusion: There remains an urgent need to evaluate and address CRC disparities in rural areas. Investigators should focus future work on assessing the quality of staging at diagnosis, treatment, and survivorship care in rural areas.

27 February 2023 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
ASAryana Sepassi
Aryana Sepassi
SGSamantha Garcia
Samantha Garcia
STSora Tanjasiri
Sora Tanjasiri
SLSunmin Lee
Sunmin Lee
MBMark Bounthavong
Mark Bounthavong
Background: Racial/ethnic minorities in the USA exhibit reduced health literacy (HL) proficiency, leading to increased health disparities. It is unclear how the effect of birth status (immigrant/US-born) affects HL proficiency among racial/ethnic minorities. Objective: To identify the direct, indirect, and total effects of birth status on HL proficiency among a nationally representative population of racial/ethnic minority adults in the USA. Design: A cross-sectional study of 2019 data from the Medial Expenditure Panel Survey. Participants: Participants aged 18 or older reporting as racial/ethnic minorities (Black, Asian, or Hispanic) with non-missing data. Main Measures: We predicted HL proficiency for each participant using a previously published model. Path analysis was used to estimate the direct, indirect, and total effects of birth status on HL proficiency, accounting for several other covariates. Prevalence ratios were estimated using adjusted Poisson regression to evaluate differences in the “Below Basic” HL category. Key Results: An estimated weighted 81,092,505 participants were included (57.5% US-born, 42.5% immigrant). More racial/ethnic minority immigrant participants fell into the lowest category of HL proficiency, “Below Basic” (14.3% vs 5.5%, p < 0.05). Results of the path analysis indicated a significant, negative direct effect of birth status on HL proficiency (standardized coefficient = − 0.24, SE = 0.01, 95%CI: − 0.26, − 0.23) in addition to an indirect effect mediated through insurance status, health-system resource use, and English proficiency. The total effect of birth status on HL proficiency was found to be − 0.29. The immigrant participant group had 81% higher prevalence of falling into the “Below Basic” HL category compared to US-born participants (prevalence ratio = 1.81, 95%CI: 1.52, 2.16). Conclusions: Immigrant status has a strong, negative, direct effect on HL proficiency among racial/ethnic minorities in the USA. This may be a result of barriers that prevent equitable access to resources that improve proper HL proficiency. US policymakers may consider several methods to reduce this disparity at the health-system-, provider-, and patient-levels.

21 August 2023 in Endocrine Practice
Verified
Journal Article
Open access
KHKeri Hurley-Kim
Keri Hurley-Kim
CVChuong Hoang Vu
Chuong Hoang Vu
NDNhat Minh Dao
Nhat Minh Dao
LTLam Chau Tran
Lam Chau Tran
SMSarah McBane
Sarah McBane
ASAryana Sepassi
Aryana Sepassi
To examine the extent to which metformin increases the risk of vitamin B12 deficiency and borderline deficiency over time in participants with type 2 diabetes (T2DM). Using the All of Us database, adults aged 18 or older with T2DM and a documented history of metformin use were included for evaluation of B12 deficiency. Those with B12 deficiency prior to metformin use were excluded. Adjusted logistic regression models were used to evaluate the association between metformin use and long-term metformin use (≥4 years), and the risk of B12 deficiency. We further conducted a subgroup analysis comparing differences in borderline B12 deficiency in metformin and non-metformin users. Of 36,740 participants with T2DM, 6,221 (16.9%) had documented metformin use. The average age of metformin users was 65.3 years. B12 deficiency was confirmed in 464 (7.5%) metformin users and 1,919 of 30,519 participants (6.3%) did not use metformin. Metformin users had a 4.7% increased risk of developing B12 deficiency compared to non-metformin users (p=0.44). Each additional year of metformin use was associated with 5% increased risk of deficiency (p<0.05). Metformin use of ≥4 years resulted in a 41.0% increased risk of B12 deficiency, compared to those who used <4 years of metformin (p<0.05). Metformin use increased the risk of borderline B12 deficiency by 27.0% (p<0.05). Long-term metformin use was associated with increased risk of B12 deficiency in T2DM patients, with compounding risk over time.

25 February 2023 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
ASAryana Sepassi
Aryana Sepassi
ISIla M. Saunders
Ila M. Saunders
MBMark Bounthavong
Mark Bounthavong
RTRandy A. Taplitz
Randy A. Taplitz
CLCathy Logan
Cathy Logan
JWJonathan H. Watanabe
Jonathan H. Watanabe
Purpose The aim of this study was to assess the cost effectiveness of letermovir prophylaxis with the option for subsequent pre-emptive therapy (PET) for the prevention of cytomegalovirus (CMV) infection compared with a PET-only scenario in adult allogeneic hematopoietic stem cell transplant (allo-HCT) recipients in the United States over a 10-year time horizon. Materials and Methods A publicly available decision tree model was constructed using a commercial third-party payer perspective to simulate an allo-HCT recipient’s clinical trajectory in the first-year post-transplant, followed by entry to a Markov model to simulate years 2 through 10. Clinical inputs and utility estimates were derived from published literature. Costs were derived from published literature and US Department of Veterans Affairs Federal Supply Schedule drug pricing. Outcomes assessed included life expectancy, quality-adjusted life-years (QALYs), direct medical costs, and the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses (PSA) were performed to test the robustness of the findings. Results Compared with PET alone, letermovir prophylaxis was projected to increase life-years per person (4.99 vs. 4.70 life-years), and increase QALYs (3.29 vs. 3.08) and costs (US$83.411 vs. US$70,698), yielding an ICER of US$59,356 per QALY gained. One-way sensitivity analyses indicated our model was sensitive to mortality (ICER: $164,771/QALY) and utility (letermovir ICER: $117,447/QALY; PET ICER: $107,290/QALY) in the first-year post-transplant. In 57.1% of the PSA simulations, letermovir was a cost-effective option using a willingness-to-pay threshold of US$100,000 per QALY. Conclusions Letermovir prophylaxis is cost effective compared with PET alone with a willingness-to-pay threshold of US$100,000 per QALY gained. Sensitivity analysis results indicate future research is required to understand the impact of mortality and quality of life in the first-year post-transplant to arrive at a conclusive decision on letermovir adoption.

25 July 2019 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
ASAryana Sepassi
Aryana Sepassi
JWJonathan H. Watanabe
Jonathan H. Watanabe
Background: More than 1.3 million emergency department visits have been associated with adverse drug events (ADEs) in older adults. Increasing Alzheimer’s disease (AD) prevalence in the geriatric population poses an additive risk of ADEs because of the array of psychotropic medications prescribed for AD patients. Scant research has been conducted at a nationwide level on psychotropic-related ADEs in this population. Objective: This study aimed to determine the incidence and economic burden of psychotropic ADEs in the geriatric AD population compared with the non-AD geriatric population. Methods: A retrospective analysis was conducted of geriatric AD patients who visited the ED in 2013 with a psychotropic-related ADE to determine the incidence and resource utilization of these events. The relationship between presence of AD and an ADE was analyzed using multiple logistic regression. Results: There were 427 969 Alzheimer’s ED visits compared with 20 492 554 ED visits without. Of the AD cases, 1.04% were associated with at least 1 adverse event. AD cases more frequently were admitted as inpatients (64.90% vs 34.92%, P < 0.01). Common drug classes associated with AD-related ADEs were benzodiazepines, antipsychotics, and autonomic nervous system–affecting agents (adrenergic agonists, antimuscarinic agents, anticholinergic agents). There was a significantly higher likelihood for Alzheimer’s cases to experience any psychotropic-related adverse event (OR = 1.66; 95% CI = 1.20, 1.82). Conclusion and Relevance: Alzheimer’s patients more frequently experienced psychotropic-related adverse events and related adverse outcomes than older adults without Alzheimer’s. Application of these findings should be implemented in protocol development to reduce future psychotropic-related adverse outcomes for this population.

10 January 2022 in Diabetes Spectrum
Verified
Journal Article
Open access
PDF file
ASAryana Sepassi
Aryana Sepassi
MBMark Bounthavong
Mark Bounthavong
RSRenu F. Singh
Renu F. Singh
MHMark Heyman
Mark Heyman
KBKristin Beizai
Kristin Beizai
JWJonathan H. Watanabe
Jonathan H. Watanabe
Measuring the population-level relationship between compromised mental health and diabetes care remains an important goal for clinicians and health care decision-makers. We evaluated the impact of self-reported unmet psychological need on health care resource utilization and total health care expenditure in people with type 2 diabetes. Patients who reported unmet psychological needs were more likely than those who did not to incur a higher annual medical expenditure, have greater resource utilization, and have a higher risk of all-cause mortality.